Guidelines

Clinical practice guidelines (CPGs) are a cornerstone of hematology/oncology practice, given the increasing complexity of the fields. On HemOnc.org, we primarily organize guidelines by the disease(s) on which they focus. For example, the HER2+ breast cancer page contains guidelines pertinent to HER2+ breast cancer, whereas the more generic breast cancer guidelines are to be found on the breast cancer page. 
Topical guidelines are to be found on the relevant page; for example, immune effector cell toxicity management guidelines are found on the IEC toxicity page.
For links directly to professional society guidelines, please visit this page.
=Major Guidelines Organizations=
==American Society of Clinical Oncology (ASCO)==
*All ASCO guidelines are published in the Journal of Clinical Oncology. Companion articles are often published in JCO Oncology Practice.
*Dedicated ASCO guidelines landing page.
**HemOnc.org ASCO guideline page
==American Society of Hematology (ASH)==
*Dedicated ASH guidelines landing page.
==American Society for Transplant and Cellular Therapy (ASTCT)==
*Dedicated ASTCT guidelines landing page.
==European Society of Medical Oncology (ESMO)==
*Many, but not all, ESMO guidelines are published in Annals of Oncology or ESMO Open. Some ESMO guidelines are published elsewhere.
*Dedicated ESMO guidelines landing page.
**HemOnc.org ESMO guideline page
==National Comprehensive Cancer Network (NCCN)==
*Some NCCN guidelines are published in JNCCN.
*Dedicated NCCN guidelines landing page
**HemOnc.org NCCN guideline page
=Other Guidelines=
A substantial number of professional organizations provide guidelines; please visit the professional organizations page to learn more. Over time, we will add links to the dedicated guidelines pages for these organizations.
*Childhood Cancer Predisposition Screening Recommendations
**American Association for Cancer Research (AACR)
***Li-Fraumeni Syndrome: 2017: Kratz et al. Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome Pubmed
***Leukemia-Predisposition: 2017: Porter et al. Recommendations for Surveillance for Children with Leukemia-Predisposing Conditions Pubmed
***DNA Repair Disorders: 2017: Walsh et al. Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders Pubmed
***Inherited Mismatch Repair Deficiency: 2017: Tabori et al. Clinical Management and Tumor Surveillance Recommendations of Inherited Mismatch Repair Deficiency in Childhood Pubmed
***Pediatric NF-1: 2017: Evans et al. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1 Pubmed
***Pediatric NF-2: 2017: Gareth & Evans et al. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders Pubmed
***Gorlin Syndrome & Rhabdoid Tumor Predisposition: 2017: Foulkes et al. Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome Pubmed
***VHL & Hereditary Pheochromocytoma/Paraganglioma Syndromes: 2017: Rednam et al. Von Hippel–Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood Pubmed
***PTEN, DICER1, FH, & Their Associated Tumor Susceptibility Syndromes: 2017: Schultz et al. PTEN, DICER1, FH, and Their Associated Tumor Susceptibility Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood Pubmed
***RASopathies: 2017: Villani et al. Recommendations for Cancer Surveillance in Individuals with RASopathies and Other Rare Genetic Conditions with Increased Cancer Risk Pubmed
***Retinoblastoma & Neuroblastoma: 2017: Kamihara et al. Retinoblastoma and Neuroblastoma Predisposition and Surveillance Pubmed
***Inherited GI Cancer Syndromes: 2017: Achatz et al. Cancer Screening Recommendations and Clinical Management of Inherited Gastrointestinal Cancer Syndromes in Childhood Pubmed
***Overgrowth Syndromes: 2017: Kalish et al. Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma Pubmed
***MEN Syndromes: 2017: Wasserman et al. Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood Pubmed
**SIOPE and CanGene-CanVar
***DICER1: 2021: Bakhuizen et al. Surveillance recommendations for DICER1 pathogenic variant carriers: a report from the SIOPE Host Genome Working Group and CanGene-CanVar Clinical Guideline Working Group Pubmed
=Quality of evidence and strength of recommendations=
==GRADE (Grading of Recommendations Assessment, Development, and Evaluation)==
#Guyatt et al. 2011 GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables EuroPMC
#Balshem et al. 2011 GRADE guidelines: 3. Rating the quality of evidence EuroPMC
Category:Guideline pages